Navigation Links
Marshall Edwards to Report new Data on Mitochondrial Inhibitor Program at American Association for Cancer Research Annual Meeting
Date:3/29/2011

SAN DIEGO, March 29, 2011 /PRNewswire/ -- Marshall Edwards, Inc.(Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that an abstract highlighting the Company's mitochondrial inhibitor program has been accepted for a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting on Monday, April 4, 2011 at 1:00 p.m. EDT at the Orange County Convention Center in Orlando.

Ayesha Alvero, M.D., Department of Obstetrics, Gynecology, and Reproductive Sciences at Yale University School of Medicine, will present new laboratory data demonstrating the ability of NV-128, Marshall Edwards' first-generation investigational compound, to significantly depress mitochondrial function and induce cell death in chemotherapy-resistant ovarian cancer stem cells.  This cell death results from the activation of two independent pathways: 1) AMP kinase leading to the inhibition of mTOR1 and mTOR2 and the induction of autophagy; and 2) mitochondrial MEK/ERK leading to mitochondrial depolarization. These data suggest that the simultaneous activation of these pathways appears to be a potent stimulus to induce cell death in a chemo-resistant ovarian cancer stem cell population identified by researchers at Yale University.

A copy of the poster, entitled "Depression of Mitochondrial Bioenergetics is a Potent Death Stimulus in the Ovarian Cancer Stem Cells," will be available immediately following Dr. Alvero's presentation at www.marshalledwardsinc.com.

Marshall Edwards has identified a next-generation compound called NV-344 that has demonstrated significantly more activity than NV-128 across a broad range of tumor cells in pre-clinical studies. The Company is in the process of completing drug manufacturing of NV-344
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novogen and Marshall Edwards Sign Asset Purchase Agreement
2. Marshall Edwards CEO to Present at Lazard Capital Markets Healthcare Conference
3. Marshall Edwards CEO to Present at JMP Securities Healthcare Conference
4. Nobel Prize Winner Robert Edwards: A Personal Memoir by the Only American Physician to Participate in Developing IVF
5. Protege of Nobel Prize Winner Robert Edwards Carries on his IVF Legacy
6. Soligenix Reports Year-End 2010 Financial Results and Highlights Recent Accomplishments
7. Reportlinker Adds Upstream Processing in Biopharmaceuticals - Increasing Use of Low-Cost Disposable Bioreactors to Drive the Upstream Bioprocessing Market
8. Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment
9. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2010 Audited Financial Results
10. Reportlinker Adds Quantum Dots: Technologies and Global Markets
11. Neogen Reports 27% Increase in Quarterly Net Income
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)...  The Chicago Bears are excited to announce the ... in an effort to raise awareness of skin cancer. ... SPOT me™ skin cancer screenings at a preseason fan ... SPOT me™ is an educational campaign designed to inform ... of skin cancer, and encourages people to get screened ...
(Date:7/30/2014)... July 30, 2014   Wyle has ... Integrated Lifecycle Mission Support Services (FILMSS) contract awarded ... Under the terms of the contract, Wyle will ... Moffett Field, Calif. In particular, Wyle will provide ... development projects on the International Space Station and ...
(Date:7/30/2014)... Yuma, AZ (PRWEB) July 30, 2014 ... , State-of-the-art facility and complementary therapies brings comprehensive ... square foot, state-of-the-art Yuma Regional Cancer Center has ... since 2012, the program includes services such as ... laboratory, massage therapy, American Cancer Society Resource Center, ...
(Date:7/30/2014)... 30, 2014  AtheroNova Inc. (OTCBB: AHRO), a ... of compounds to safely regress atherosclerotic plaque and ... its partner, CardioNova, has accomplished first dosing of ... AtheroNova,s lead compound, AHRO-001.  This Phase 1b trial ... 1 safety trial completed in February 2014, in ...
Breaking Biology Technology:Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4
... (Nasdaq: BNVI ) today announced financial ... "Scientific development, regulatory progress and growth accurately characterize ... chairman and chief executive officer. "We successfully laid ... is essential for the successful approval and marketing ...
... Corporation (NYSE: SGP ) is scheduled to ... first quarter on Tuesday, April 21, 2009. At ... a conference call to review results for the 2009 ... and other members of management will host the conference ...
... LLC, and Burrill & Company Collaborating on Strategic ... 12 Developer Tower Investments, LLC ("Tower"), and ... ("Burrill") today announced a formal partnership with aims ... planned development and funding related to the "shovel-ready" ...
Cached Biology Technology:Bionovo Announces 2008 Highlights and Year-End Financial Results 2Bionovo Announces 2008 Highlights and Year-End Financial Results 3Bionovo Announces 2008 Highlights and Year-End Financial Results 4Bionovo Announces 2008 Highlights and Year-End Financial Results 5Bionovo Announces 2008 Highlights and Year-End Financial Results 6Bionovo Announces 2008 Highlights and Year-End Financial Results 7Bionovo Announces 2008 Highlights and Year-End Financial Results 8Bionovo Announces 2008 Highlights and Year-End Financial Results 9Bionovo Announces 2008 Highlights and Year-End Financial Results 10Elk Run Developers Announce Partnership with Leading Life Sciences Firm 2Elk Run Developers Announce Partnership with Leading Life Sciences Firm 3Elk Run Developers Announce Partnership with Leading Life Sciences Firm 4
(Date:7/30/2014)... major interest in neuroscience. A large number of ... of Wallerian degeneration: transcription factor activation, immune response, ... responses in the distal segment of the sciatic ... in gene expression between the proximal and distal ... from Nantong University, China used microarrays to analyze ...
(Date:7/30/2014)... spinal cord injury (SCI), traumatic brain injury (TBI) and ... has been learned over the past 30 years regarding ... regulate axon growth, but this large body of information ... Lemmon and his team from University of Miami in ... but a consensus is emerging that one contributing factor ...
(Date:7/30/2014)... 3,000 pieces is still in its infant stage. But ... of major significance. "Amazingly often, we are findingin addition ... that we found in Baltic amber," explained Bonn paleontologist ... comes from the Baltic Sea region, which is almost ... e.g., the coastal regions of Mecklenburg, Poland and Belarus. ...
Breaking Biology News(10 mins):Chinese mosquitos on the Baltic Sea 2
... stress a typical married couple feels during an ordinary half-hour ... from wounds by at least one day, a new study ... routinely hostile toward each other, the delay in that healing ... have major financial implications for medical centers and health care ...
... an AIDS vaccine, UCLA AIDS Institute researchers report the ... the infection in different ways. , Detailed in the ... ( http://jvi.asm.org ), the findings show that the body's ... determined. , The researchers followed the cases of male ...
... much more sophisticated visual system than previously thought, according ... which bees were able to solve complicated colour puzzles. ... of the most difficult challenges of vision - namely, ... by suggesting that bees solve this problem using their ...
Cached Biology News:Stress substantially slows human body's ability to heal 2Stress substantially slows human body's ability to heal 3UCLA scientists discover immune response to HIV differs, even in identical twins 2Bees solve complex colour puzzles 2
Rabbit Serum New Zealand or California Origin...
Collected from 8-12 week old New Zealand or Californian rabbits. Aseptically collected and processed to minimize hemolytic activity. Pricing: $60/unit for 1 - 10 units...
... , Customer Peptide Synthesis , Containing one Phospho-Amino Acid ... will be returned to customer conjugation of peptide to KLH protein ... Maintenance 102 days/each , Pre-immune bleed x1 ... , Test bleed (app. 5 ml) x1 /each ...
... collected off the clot fasted non-Swiss Albino mice of ... Anticoagulants: N-02: Citrate N-04: ... Potassium Oxalate N-10: EDTA (Na) N-03: ... CPD N-09: K3EDTA N-11: Heparin ...
Biology Products: